Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06372496
Status:
RECRUITING
Last Update Posted:
2024-05-22
First Post:
2024-04-15
Brief Title:
Pragmatic Open - Label Randomized Clinical Trial of FFUMECVI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase 4 52-week Primary Analysis at 24-weeks Randomized Stratified Open-label Active-controlled Parallel-group Effectiveness Study Comparing FFUMECVI With Non-ellipta Usual Care ICSLABA in Adult Participants With Uncontrolled Asthma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to assess and compare the effectiveness of fluticasone furoateumeclidinium bromidevilanterol trifenatate FFUMECVI with inhaled corticosteroidslong-acting beta-2 agonists ICSLABA in adult participants with uncontrolled asthma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None